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Human chromogranin A (CgA), a 48-kDa protein encompassing
439 amino acids, belongs to the granin family and is widely
distributed in secretory granules of endocrine and neuroendocrine
cells (Konecki et al, 1987; Simon and Annis, 1989; Cetin and
Grube, 1991). 
CgA, secreted with the co-resident hormones, contains multiple
dibasic sites important for proteolytic processing occurring at
intragranular and extracellular levels. CgA thus behaves as a
prohormone generating several bioactive peptides exerting
intracrine, autocrine, paracrine and endocrine effects (Barbosa 
et al, 1991; Metz-Boutigue et al, 1993; Helle and Angeletti, 1994;
Strub et al, 1996). 
CgA, being co-stored and co-released with native hormones, is
regarded as a useful tissue marker for a variety of neuroendocrine
cells (Weiler et al, 1987; Deftos et al, 1988; Totsch et al, 1992;
Rosa and Gerdes, 1994) and a possible sensitive circulating
marker of neuroendocrine tumours (NET). Indeed high plasma
CgA levels in patients with endocrine and neuroendocrine
tumours, including phaeochromocytoma, have been reported
(O’Connor and Bernstein, 1984; O’Connor et al, 1984; O’Connor
and Deftos, 1986; Sobol et al, 1986; Hsiao et al, 1990a; Hsiao et al,
1990b; Deftos, 1991; Grondal et al, 1991; Hsiao et al, 1991;
Johnson et al, 1993; Canale and Bravo, 1994; Kimura et al, 1997;
Stridsberg and Husebye, 1997). In addition, CgA seems to reflect
the secretory activity and burden of NET (Hsiao et al, 1990b;
Grondal et al, 1991; Hsiao et al, 1991) and sometimes appears to
be the only secretory product of hormone-negative endocrine
(Sobol et al, 1989) and non-endocrine tumours (Deftos, 1991;
Baudin et al, 1998). 
Detection of the CgA antigen may therefore be of great clinical
interest in differential diagnosis of suspected secretory tumours
and in their follow-up. Circulating CgA was measured in earlier
studies by several competition assays with different results
(O’Connor and Bernstein, 1984; Dillen et al, 1989). However,
since CgA is exposed to intensive proteolytic activity, sandwich
methods involving monoclonal or polyclonal antibodies were
subsequently developed (Bender et al, 1992; Syversen et al, 1994;
Corti et al, 1996). Recently, Degorce et al (1999) introduced a
two-site sandwich immunoradiometric assay with monoclonal
antibodies directed against the median part of the protein, less
exposed to proteolysis. By this method, Baudin et al (1998)
showed that measurement of circulating CgA is a good marker for
neuroendocrine tumours without highly conserved eutopic secre-
tions, while its validity for phaeochromocytomas was still to be
proven. 
In the present paper we investigated whether plasma CgA, as
evaluated by this new assay, is a predictor of phaeochromocytoma
and of other-NET. In addition, we explored the possibility that
CgA represents the only secretory product of apparently nonfunc-
tioning solid adrenocortical tumours. 
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Summary We investigated whether plasma chromogranin A (CgA), measured by a new immunoradiometric assay, may be a sensitive and
specific marker of phaeochromocytoma and of other neuroendocrine tumours. This study involved 121 patients of whom 20 with
phaeochromocytoma, 28 with other neuroendocrine tumours (19 gastroenteropancreatic tumors, 3 medullary thyroid and 6 small cell lung
carcinomas), 25 with solid nonfunctioning adrenocortical tumours and 48 with essential hypertension. In addition, 130 normal subjects were
taken as controls. Plasma catecholamines were measured by using high-performance liquid chromatography, and CgA by a two-site sandwich
immunoradiometric assay involving monoclonal antibodies raised against the unprocessed central domain (145–245) of human CgA. Plasma
CgA in controls (49.0 ± 3.1 ng ml–1, mean ± SE) and in essential hypertensives (50.8 ± 3.5 ng ml–1) was lower (P < 0.0001) than in adrenocortical
tumours (91.8 ± 13.2 ng ml–1), in phaeochromocytomas (254 ± 49 ng ml–1) and in patients with other neuroendocrine tumours (469 ± 84 ng ml–1).
Plasma CgA and catecholamines identified 13 and 18 out of 20 phaeochromocytomas with sensitivity of 65% and 90%, respectively. Combined
measurement of both markers improved sensitivity up to 100%. In the other neuroendocrine tumours, CgA was abnormal in 23/28 cases
(sensitivity 82%) and in 6 it was the only circulating marker of disease. In gastroenteropancreatic tumours, CgA measurement identified all cases
(sensitivity 100%). Specificity of CgA in patients with essential hypertension was 98%. In conclusion, CgA determination showed high sensitivity
in identifying gastroenteropancreatic tumours and, in association with catecholamines, in detecting patients with phaeochromocytoma. CgA
sometimes appeared to be the only circulating marker of disease. Since the specificity of CgA proved to be excellent, this assay may be useful
for diagnosis both of functioning and non-functioning neuroendocrine tumours. © 2001 Cancer Research Campaign http://www.bjcancer.com
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Subjects 
121 patients (63 males, 58 females; mean ± SD age 49.8 ± 16.8
years; range 14–79 years) were enrolled. 48 had NET: 20
phaeochromocytoma, 3 medullary thyroid carcinoma, 6 small cell
lung carcinoma and 19 gastroenteropancreatic tumours. 48
patients had essential hypertension and 25 patients had solid
nonfunctioning adrenocortical tumours. Finally, 130 normal
subjects were taken as controls. Demographic and clinical data of
controls and of all patients are given in Table 1. 
Essential hypertension, defined as recently reported (JNC VI),
was confirmed after exclusion of all forms of secondary hyper-
tension. In addition, in no case did CT or NMR show adrenal or
abdominal masses. To further strengthen the diagnosis, these
patients had been followed-up for at least 2 years and their blood
pressure appeared to be well controlled with conventional anti-
hypertensive therapy. 
In patients with phaeochromocytoma, diagnosis was based on
high plasma and urinary catecholamines or abnormal response to
the glucagon test, and presence of adrenal or abdominal masses 
on CT or NMR (mean size 4.42 cm, range 2–7 cm). In 6 cases,
metaiodobenzylguanidine scintigraphy further confirmed the dia-
gnosis. Phaeochromocytomas were located at the adrenal level in
all cases except one (para-aortic paraganglia). 15 phaeochromo-
cytomas were sporadic and 5 familial (4 patients had multiple
endocrine neoplasia type II, 1 had neurofibromatosis). In all
patients diagnosis was confirmed by pathological analysis after
surgery. Humoral follow-up and imaging data revealed 18 benign
and 2 malignant tumours. 
In patients with other-NET, diagnosis was established on the
basis of clinical signs and symptoms, conventional imaging
methods (CT, somatostatin receptor scintigraphy, angiography)
and abnormal specific humoral markers (calcitonin, neuron-
specific enolase, pancreatic polipeptide, serotonin, gastrin,
carcinoembryonic antigen, a-subunit of glycoprotein, IGF-1). In
all cases diagnosis was histologically confirmed. Gastroentero-
pancreatic tumours were classified according to their embryo-
logical origin: 10 patients had foregut-derived tumours
(1 duodenum and 9 pancreas) and 9 had midgut-derived tumours
(ileum and right colon). 
Evaluation of patients with adrenocortical tumours was as
follows: the majority (n = 19) were discovered in hypertensive
patients during routine analysis to exclude secondary forms of
hypertension. 6 tumours were incidentally found in normotensive
patients after abdominal ultrasound performed for hepatic (n = 4)
or genito-urinary disorders (n = 2). In all cases, CT (n = 23) or
NMR (n = 2) showed solid masses (18 unilateral and 7 bilateral)
with size ranging from 10 to 40 mm (23.8 ± 1.6 mm, mean ± SE)
and with apparently benign features. The hormonal study excluded
abnormal activity of any of the following: adrenal medulla 
(basal plasma and urinary catecholamines and plasma cate-
cholamines after 1 mg glucagon injection, when indicated), renin-
angiotensin-aldosterone system (urinary aldosterone and plasma
renin activity and aldosterone in upright position), glucocorticoids
(urinary free cortisol, plasma cortisol before and after dexametha-
sone, plasma ACTH), androgens (free and total testosterone) and
steroid precursors (plasma dehydroepiandrosterone sulphate, andro-
stenedione and 17-OH-progesterone). When hormonal values
resulted to be borderline an adrenal scintigraphic evaluation
(metaiodobenzylguanidine- or 131-I norcholesterol-scintigraphy)
was also requested. 
The exclusion criterion for this study was renal failure with
plasma creatinine >133.6 mM l–1 (1.5 mg dl–1) in order to avoid the
well-known false positive results of CgA in this disease. 
Experimental design 
All patients gave their informed consent to the study, which was
approved by the local Ethical Committee. Patients taking drugs
observed a pharmacological wash-out for at least 2 weeks prior
to the study. However, 11 patients maintained antihypertensive
therapy because of severe hypertension and/or target-organ
damage, 4 were taking insulin or oral antidiabetics, 2 were on H2-
antagonists and 2 on peripheral opioid-agonists. No patient with
other-NET had started chemotherapy or somatostatin analogues
prior to the study. All subjects maintained their usual diet with
controlled salt intake (80–100 mEq day–1 sodium and 60–
80 mEq day–1 potassium). 
Tests were performed in the morning (08.00–09.00 h), after
overnight fasting and in supine position. An indwelling 21-gauge
scalp vein needle inserted in an antecubital vein was used for
blood sampling. Controls underwent a blood sample after 30
minutes for measurement of plasma CgA and creatinine while 
the patients were also tested for noradrenaline and adrenaline
determination. 3 patients with essential hypertension, 5 with
phaeochromocytoma and 12 with adrenocortical tumours were
also submitted to a dynamic test (catecholamine determination
before and 2’ after 1 mg glucagon injection) to better define the
diagnosis. In patients with phaeochromocytoma, blood samples
for catecholamines and CgA were also obtained after surgery
(range 15–30 days) in 7 cases (6 benign and 1 malignant). 
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Table 1 Demographic and clinical data of normotensive controls (C) and of patients with essential hypertension (EH), phaeochromocytoma (PHEO), other
neuroendocrine tumours (other-NET) and with adrenocortical tumours (AT). Mean±SE and range (in parentheses) are reported 
Patients C  EH  PHEO  other-NET  AT 
No. 130  48  20  28  25 
Sex (M/F)  86/76  17/31  12/8  16/12  13/12 
Age (yr)  41.5 ± 2.0 (19–72)  42.7 ± 1.84 (21–70)  40.6 ± 3.9 (14–76)  60.0 ± 3.5# (16–79)  60.3 ± 1.9# (40–77) 
SBP (mmHg)  127.2 ± 1.9**§§˚  148.0 ± 2.6  163.5 ± 7.2*  129.0 ± 2.0**§§˚  153.4 ± 3.7 
DBP (mmHg)  75.9 ± 1.7**§§˚  96.0 ± 1.2  102.2 ± 4.7  77.5 ± 1.4**§§˚  91.0 ± 2.2 § 
HR (bpm)  68.7 ± 1.4  70.5 ± 1.2  79.8 ± 2.6  69.0 ± 1.6  69.2 ± 1.9 
Pl. Creat. (mM l–1)  77.0 ± 1.7 (44–106)  79.5 ± 1.7 (53–115)  73.4 ± 3.5 (38–133)  76.0 ± 2.6 (44–115)  95.5 ± 4.4 (53–133) 
M/F: male/female, SBP: systolic blood pressure, DBP: diastolic blood pressure, HR: heart rate, Pl creat: plasma creatinine. * P < 0.01; **P < 0.001 vs EH; 
§ P < 0.02; §§ P < 0.001 vs PHEO; ° P < 0.001 vs AT; # P < 0.0001 vs C, EH and PHEO. 638 GP Bernini et al 
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Assays 
Plasma creatinine was measured by a standard technique. Plasma
catecholamines and CgA were measured using the same blood
sample collected in chilled anticoagulated (EGTA plus L-
glutathione reduced for catecholamines; heparin and Trasylol for
CgA) glass tubes. Blood was spun down in a refrigerated
centrifuge and the plasma stored at –80˚C until the assay.
Catecholamines and CgA were then assayed in duplicate and in the
same run. 
Catecholamines were analysed by high-performance liquid
chromatography, as previously described (Krstulovic et al, 1981).
The reference range for NA was <400 pg ml–1 and for A
<80 pg ml–1 in supine position. 
CgA was measured by using a novel solid-phase two-site
immunoradiometric assay based on monoclonal antibodies that
bind to two distinct contiguous epitopes within the 145–245 region
of CgA (CgA-RIA CT, Cis bio international) (Degorce et al,
1999). The first antibody is coated on the solid phase, the second,
used as a tracer, is radiolabelled with iodine 125. CgA present in
the standards (recombinant hCgA) is sandwiched between the 2
antibodies. Thus, by using antibodies directed against the median
part of the protein, only the region of CgA unexposed to proteo-
lytic processes is involved, allowing detection of the intact form
and only the major fragments of the molecule comprising the
145–245 domain. 
Statistical analysis 
Variables are expressed as mean, standard error and range. Since in
our population, circulating CgA and catecholamines were not
normally distributed, analyses were performed using untrans-
formed and log-transformed data. Spearman correlation coeffi-
cients were used as parameters of association. The results of
hormonal secretion were analysed as positive or negative.
Krunskal-Wallis and Wilcoxon tests were performed for each vari-
able to compare groups. P levels lower than 0.05 were considered
statistically significant. 
RESULTS 
Intra-assay and interassay coefficient variations of our CgA
method are 2.5% and 7.0%, respectively. Assay detection limit is
1.5 ng ml–1 (the smallest detectable concentration different from 0
with a probability of 95%). Values obtained with anticoagulated
plasma in 130 normal subjects were: median 44.3 ng ml–1; range
21–98.6 ng ml–1. A cut-off value was fixed at 100 ng ml–1. 
As shown in Table 1, controls and patients with essential hyper-
tension and phaeochromocytoma were younger (P < 0.0001) than
the other 2 groups. Apart from controls, patients with other-NET
showed lowest and those with phaeochromocytoma highest blood
pressure levels, while blood pressure was similar in patients with
essential hypertension and with adrenocortical tumours. No statist-
ical difference in plasma creatinine was found among groups. 
CgA levels in essential hypertensives (50.8 ± 3.5 ng ml–1) were
similar to normotensive controls (49.0 ± 3.1 ng ml–1). As shown in
Figure 1, where data are log-transformed, CgA in patients with
essential hypertension was significantly (P < 0.0001) lower than in
those with solid cortical adrenal tumours (91.8 ± 13.2 ng ml–1),
phaeochromocytoma (254.0 ± 49.2 ng ml–1) and other-NET
(469.5 ± 83.8 ng ml–1). 
Individual data of patients with phaeochromocytoma (n = 20)
showed that supine plasma noradrenaline was elevated in 18
(90%), adrenaline in 4 (20%) and CgA in 13 (65%) cases (Figure 2).
Thus, we found 2 false negative results for noradrenaline, 16 for
adrenaline and 7 for CgA. Noradrenaline and CgA were elevated
simultaneously in 11 patients (55%), while adrenaline and CgA in
3 patients (15%). Raised CgA levels associated with normal nor-
adrenaline and adrenaline were found in 2 (10%) and in 10 (50%)
cases, respectively. Normal CgA associated with elevated
noradrenaline and adrenaline was found in 7 (35%) and in 1 (5%)
patients, respectively. In summary, the sensitivity of CgA
measurement in identifying patients with phaeochromocytoma
was 65%, while that of noradrenaline and of adrenaline was 90%
and 20%, respectively. However, CgA measurement in addition to
catecholamines improved sensitivity up to 100%. 
Log-transformed CgA levels of patients with other-NET (n =
28) are shown in Figure 3. In this group gastroenteropancreatic
tumours (607 ± 106 ng ml–1) were associated with higher CgA
levels than small cell lung tumours (145 ± 42 ng ml–1, P < 0.02)
and medullary thyroid carcinomas (249 ± 209 ng ml–1). Individual
data showed that in the whole group plasma CgA was greater than
normal in 23/28 cases (82%), while in gastroenteropancreatic
tumours this finding was observed in all cases (100%). The 5 false
negative results were found in 3 out of 6 small cell lung cancers
and in 2 out of 3 medullary thyroid carcinomas. CgA and other
markers (specific tumoral markers and/or catecholamines) were
simultaneously elevated in 17 patients (61%). In 6 cases CgA was
found to be the only circulating marker of disease (4 intestinal
carcinoids and 2 pancreatic tumours). Thus, sensitivity of the
CgA assay in detecting patients with other-NET was 82%, while
it was 100% in identifying gastroenteropancreatic tumours.
Considering phaeochromocytomas and other-NET as a single
group (n = 48), plasma CgA detected the disease in 36 patients
(75%), in 8 of whom it was the only circulating marker of disease
(17%). 
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Figure 1 Plasma log-transformed CgA levels in patients with essential
hypertension (EH), adrenocortical tumours (AT), phaeochromocytoma (PHEO)
and with other neuroendocrine tumours (other-NET). Individual data and
means (±SE) are reported. The dashed line indicates the upper limit of the
normal range. # P < 0.0001 vs EH; & P < 0.001 vs AT; § P < 0.05 vs 
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In patients with adrenocortical tumours (n = 25), supine adren-
aline was above the normal range in 1 (4%), noradrenaline in 3
(12%) and CgA in 6 (24%) cases (Figure 4). Plasma noradrenaline
and CgA levels were elevated simultaneously in 1 patient (4%),
while adrenaline and CgA in no case. Normal CgA associated with
elevated noradrenaline and adrenaline was found in 2 (8%) and in
1 (4%) patients, respectively. 17 patients (68%) were negative for
both noradrenaline and CgA, and 18 (72%) for both adrenaline and
CgA. In the patients with abnormal catecholamines and/or CgA
values, diagnosis of phaeochromocytoma was fully excluded
in all cases by normal response to the glucagon test, absent
metaiodobenzylguanidine-scintigraphy uptake and by radiological
features on NMR. 
Finally, in essential hypertensives (n = 48), supine plasma
adrenaline was in the normal range in all cases, while noradren-
aline was elevated in 3 patients (6.2%). Only in 1 case (2.1%) was
circulating CgA above normal limits (Figure 5). No patient had
catecholamines and CgA simultaneously abnormal. Thus, plasma
adrenaline gave no false positive results in patients with essential
hypertension, whereas noradrenaline and CgA showed 3 and 1
false positive results, respectively. Consequently CgA specificity
was 98%, while that of adrenaline and noradrenaline was 100%
and 94%, respectively. 
Associations 
Weak positive correlation was found between CgA and plasma
noradrenaline in patients with phaeochromocytoma (r = 0.477, P <
0.05). No correlation was found between CgA and adrenaline,
blood pressure or plasma creatinine either in the group as a whole
or in the subgroups. No association was found between tumour
size of patients with phaeochromocytoma and plasma CgA or 
catecholamines. 
Follow-up 
All patients with phaeochromocytoma in whom plasma CgA was
measured before and after surgery normalized CgA levels, except
the patient with recurrence of the disease due to malignant
phaeochromocytoma (380 vs 383 ng ml–1). 
DISCUSSION 
The development of a new method to measure CgA has raised new
interest in this protein as a putative circulating marker of neuro-
endocrine tumours (Degorce et al, 1999). This immunoradiometric
assay, based on monoclonal antibodies, makes it possible to bind a
region of CgA unexposed to proteolytic processes and, conse-
quently, to detect the intact form and also the major fragments of
the molecule. This characteristic offers advantages when CgA is
evaluated in pathological conditions where a different proteolysis
may generate a variability of the fragments in biological fluids.
For example, in patients with phaeochromocytoma, and perhaps
with other endocrine tumours, CgA circulates in at least 3 forms
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Figure 3 Plasma log-transformed CgA levels in patients with other
neuroendocrine tumours (other-NET) as a whole and subgroups:
gastroenteropancreatic (GEP) tumours, small cell lung cancers (SCLC),
medullary thyroid carcinomas (MTC). Individual data and means ± (SE) are
reported. The dashed line indicates the upper limit of the normal range. 
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Figure 2 Plasma supine noradrenaline (above) and adrenaline (below) and
CgA levels in patients with phaeochromocytoma. The horizontal dashed lines
are the upper normal limit for catecholamines while the vertical dashed lines
the upper normal cut-off for CgA levels 640 GP Bernini et al 
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with similar molecular weights but different immunoreactivity
(Corti et al, 1996). Therefore, a method evaluating both intact
sequence and major fragments of CgA may be useful in clinical
practice. 
In the present study we included a large group of patients with
phaeochromocytoma. Sensitivity of plasma CgA in detecting this
disease reached 65%, a percentage lower than that observed by
other authors (Grondal et al, 1991; Canale and Bravo, 1994;
Nobels et al, 1997; Stridsberg and Husebye, 1997) who utilized
polyclonal radioimmunoassays, but very similar to that of Baudin
et al (1998) using the same immunoradiometric method. In addi-
tion, our data confirm that phaeochromocytomas usually cosecrete
catecholamines and CgA (Grondal et al, 1991; Kimura et al, 1997;
Baudin et al, 1998) but also show that occasionally they release
only the latter compound. Indeed, in 2 patients with histologically
proven phaeochromocytoma, catecholamines were in the normal
range while plasma CgA was very high, demonstrating that 
CgA was the only circulating marker of disease (Grondal et al,
1991; Stridsberg and Husebye, 1997). Therefore, we agree with
Stridsberg and Husebye (1997) that measuring of plasma cate-
cholamines in addition to CgA improves diagnostic sensitivity in
identifying all true-positive patients, including those with
hormone-negative tumours (Sobol et al, 1989). Finally, on the
basis of our data, circulating CgA was also found to be useful in
following up the patients after surgery. Normalization of plasma
CgA occurred in all patients with phaeochromocytoma after
removal of the mass, while persistence of high values indicated
recurrence of disease in the case of maligant phaeochromocytoma
(Grondal et al, 1991; Kimura et al 1997; Stridsberg and Husebye,
1997). 
Our study was not planned to compare sensitivity and speci-
ficity between CgA and the other tumoral markers in patients with
other-NET. However, we confirm that plasma CgA is an excellent
predictor of disease, especially in gastroenteropancreatic tumours
(O’Connor and Deftos, 1986; Eriksson et al, 1990; Nobels et al,
1997; Baudin et al, 1998) which were identified in all cases. As
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CgA levels in patients with solid nonfunctioning adrenocortical tumours. The
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already reported for phaeochromocytomas, in this group a
frequent cosecretion of CgA and of other tumoral markers was
likewise observed (Nobels et al, 1997; Baudin et al, 1998) and
CgA was sometimes found to be the only humoral predictor of
disease (Baudin et al, 1998; Ferrari et al, 1998; Nobels et al, 1998).
Thus, CgA can be used as a serum marker not only for the
functioning but also for the so-called ‘non-functioning’ neuro-
endocrine tumours. The small number of patients with medullary
thyroid carcinoma and small cell lung carcinoma included in the
present study does not allow to establish whether CgA, by our
method, is adapted when compared to more specific markers such
as calcitonin (Blind et al, 1992) and neuron-specific enolase
(Akoun et al, 1985), respectively. Therefore, at the present, CgA
has not to be considered the first choice marker of these tumours. 
In the present paper we included also solid adrenocortical
tumours without apparent secretory activity. We unexpectedly
found 6 patients with elevated CgA levels, a figure much higher
than that observed in essential hypertensives, despite superimpos-
able blood pressure and plasma creatinine values. We have no clear
explanation for this finding. However, coexistent unknown
tumours, nests of medullary tissue included in the cortical adenoma
(Bornstein et al, 1999) or a neuroendocrine differentiation of the
adrenal tumour itself (Miettinen, 1992; Li et al, 1998) cannot be
excluded to explain the high CgA levels in these patients. 
At variance with other reports (Nobels et al, 1997; Baudin et al,
1998), we finally studied an extensive population of patients
without tumours, i.e. essential hypertensives. Though previous
data (O’Connor, 1985; Hsiao et al, 1991; Canale and Bravo, 1994)
indicated that plasma CgA is higher in hypertensives than in
normotensives, no information is available with this new method.
Our results show that circulating CgA of essential hypertensive
patients is similar to that of normotensive controls and almost
constantly in the normal range, thus confirming the high speci-
ficity of this humoral marker (Hsiao et al, 1991; Canale and Bravo,
1994; Nobels et al, 1997; Baudin et al, 1998). 
In conclusion, CgA measurement with this new assay shows
good sensitivity in identifying gastroenteropancreatic tumours and,
in association with catecholamine determination, in detecting
patients with phaeochromocytoma. Furthermore, plasma CgA
sometimes appears to be the only humoral marker of disease. Thus
the CgA assay, also for its high specificity, may be a precious tool to
diagnose both functioning and non-functioning neuroendocrine
tumours. 
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